Science Explorer Back to mapMap

Most cited papers from Advicenne Pharma (France)

What are the most cited papers from Advicenne Pharma (France)?

The most cited paper from Advicenne Pharma (France) is "Efficacy of oral midazolam for minimal and moderate sedation in pediatric patients: A systematic review" (Maria A. Manso-Silván, Catherine Guittet, François Vandenhende et al., 2019), with 73 citations. Next come "Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin" (24) and "Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments" (23).

Showing 25 of 25 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Efficacy of oral midazolam for minimal and moderate sedation in pediatric patients: A systematic review Maria A. Manso-Silván, Catherine Guittet, François Vandenhende et al. · Pediatric Anesthesia ReviewOpen access 20 Sep 2019 73
2 Population pharmacokinetic evaluation of ADV6209, an innovative oral solution of midazolam containing cyclodextrin Frédéric Marçon, Catherine Guittet, Maria A. Manso-Silván et al. · European Journal of Pharmaceutical Sciences Open access 6 Dec 2017 24
3 Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatments Aurélia Bertholet-Thomas, Catherine Guittet, Maria A. Manso-Silván et al. · Pediatric Nephrology Open access 26 Jul 2020 23
4 Safety, efficacy, and acceptability of ADV7103 during 24 months of treatment: an open-label study in pediatric and adult patients with distal renal tubular acidosis Aurélia Bertholet‐Thomas, Catherine Guittet, Maria A. Manso-Silván et al. · Pediatric Nephrology Open access 26 Feb 2021 17
5 A Two-way Randomized Cross-over Pharmacokinetic and Pharmacodynamic Study of an Innovative Oral Solution of Midazolam (ADV6209) Catherine Guittet, Maria A. Manso-Silván, Ingrid Burton et al. · Pharmaceutical Research 2 Jun 2017 15
6 Sultiame pharmacokinetic profile in plasma and erythrocytes after single oral doses: A pilot study in healthy volunteers Kim Dao, Paul Thoueille, Laurent Arthur Decosterd et al. · Pharmacology Research & Perspectives Open access 28 Jan 2020 13
7 Innovative prolonged-release oral alkalising formulation allowing sustained urine pH increase with twice daily administration: randomised trial in healthy adults Catherine Guittet, Caroline Roussel‐Maupetit, Maria A. Manso-Silván et al. · Scientific Reports Open access 18 Aug 2020 12
8 Epidemiology of Distal Renal Tubular Acidosis: A Study Using Linked UK Primary Care and Hospital Data F. Bianic, Florent Guelfucci, Ludovic Robin et al. · ˜The œNephron journals/Nephron journals Open access 2021 11
9 Bone mineral density and growth changes in patients with distal renal tubular acidosis after two-years treatment with a new alkalizing drug (ADV7103) Aurélia Bertholet‐Thomas, Maria A. Manso-Silván, Víctor Manuel Navas-Serrano et al. · Nefrología (English Edition) Open access 16 Dec 2022 5
10 Lived experiences of patients with distal renal tubular acidosis treated with ADV7103 and of their caregivers: a qualitative study Michaël Acquadro, Alexia Marrel, Maria A. Manso-Silván et al. · Orphanet Journal of Rare Diseases Open access 28 Mar 2022 5
11 An innovative ethosuximide granule formulation designed for pediatric use: Comparative pharmacokinetics, safety, tolerability, and palatability profile versus reference syrup Léonore Diezi, Kim Dao, Vincent Jullien et al. · Pharmacology Research & Perspectives Open access 20 Dec 2022 4
12 Improved growth of a child with primary distal renal tubular acidosis after switching from a conventional alkalizing treatment to a new prolonged-release formulation containing potassium citrate and potassium bicarbonate: lessons for the clinical nephrologist Olivia Boyer, Maria A. Manso-Silván, Sophie Joukoff et al. · Journal of Nephrology Open access 31 Mar 2022 4
13 AdviceMedica, une collaboration intelligente au service des patients Pascal M. Demoly, M. Demoly, J.‐L. Bourrain · Revue française d'allergologie Open access Feb 2020 3
14 PUK8 THE ECONOMIC IMPACT AND VARIABILITY OF MANAGING DISTRAL RENAL TUBULAR ACIDOSIS (DRTA) IN THE UK HEALTHCARE SETTING A. Mumford, John Everett Mumford, Saurabh Donald et al. · Value in Health Open access Nov 2019 3
15 POSB343 Living with Distal Renal Tubular Acidosis (DRTA): Qualitative Research with Patients, and Caregivers, and Nephrologists C Silva, Linda Law, Patricia E. Koochaki et al. · Value in Health Open access 2022 1
16 Comment aborder les difficultés de financement selon les phases de développement des produits ? Luc‐André Granier · La Presse Médicale 16 Apr 2010 1
17 6-year treatment follow-up with an extended-release alkaline formulation (Sibnayal®) in primary distal renal tubular acidosis Aurélia Bertholet‐Thomas, Aurélie De Mul, Julie Bernardor et al. · Orphanet Journal of Rare Diseases Open access 13 Aug 2025 0
18 Long-term clinical outcomes with an average of 6 years follow-up in dRTA patients treated with ADV7103 an oral twice-daily fixed and prolonged-release combination of potassium bicarbonate and potassium citrate (Sibnayal®). Aurélia Bertholet‐Thomas, Aurélie De-Mul, Gwenaëlle Roussey‐Kesler et al. · Research Square PreprintOpen access 18 Dec 2024 0
19 #2746 Long-term benefits in dRTA patients treated with Sibnayal®, a prolonged-release combination of potassium bicarbonate and citrate: 6-year results Aurélia Bertholet‐Thomas, Julie Bernardor, Aurélie De Mul et al. · Nephrology Dialysis Transplantation Open access May 2024 0
20 The Role of a Patient Navigator in Reducing Health Disparities in a Distal Renal Tubular Acidosis Decentralized Clinical Trial Cynthia J. D’Alessandri-Silva, Bradley P. Dixon, Carol Ogg et al. · Journal of the American Society of Nephrology Oct 2021 0
21 Use of Software as a Medical Device to Improve Therapeutic Adherence in Patients With Hematological Malignancies: Prospective Interventional MargheRITA Study (Preprint) Serena Camilla Dalto, Antonella Romanelli, Martina Violati et al. PreprintOpen access 18 Apr 2024 0
22 Living with Distal Renal Tubular Acidosis: Qualitative Research with Nephrologists, Patients, and Caregivers Cynthia J. D’Alessandri-Silva, Patricia E. Koochaki, Selam Shah et al. · Research Square PreprintOpen access 5 Apr 2021 0
23 P0003ADHERENCE BENEFITS OF ADV7103, AN INNOVATIVE PROLONGED-RELEASE ORAL COMBINATION PRODUCT, IN PATIENTS WITH DISTAL RENAL TUBULAR ACIDOSIS Aurélia Bertholet‐Thomas, Catherine Guittet, Maria A. Manso-Silván et al. · Nephrology Dialysis Transplantation Open access Jun 2020 0
24 Evaluation of the pharmacodynamics effects of an innovative prolonged release alkalinizing formulation in the urine parameters in healthy adult subjects A. Bertholet, Catherine Guittet · Archives de Pédiatrie Dec 2017 0
25 Étude clinique de phase II d’une solution orale pédiatrique de midazolam à 0,2 % (OZALINE®) pour la prémédication anesthésique Frédéric Marçon, Aurélien Legrand, Catherine Guittet et al. · Anesthésie & Réanimation Sep 2015 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.